Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling

Biochemical Pharmacology

Volumn 72, Issue 1, 2006, Pages 53-61

  Robinson, Stephanie A ^a   Rosenzweig, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; Insulin like growth factor antagonist; Insulin like growth factor binding proteins; Insulin like growth factor 1; Structure function

Indexed keywords

ARGINYLASPARAGINYLCYSTEINYLPHENYLALANYLGLUTAMYLSERYLVALYLALANYLALANYL LEUCYLLEUCYLARGINYLARGINYLCYSTEINYLMETHIONYLTYROSYLGLYCINAMIDE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPEPTIDE; HEXAPEPTIDE; IODINE 125; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTAGONIST; TRITIUM; UNCLASSIFIED DRUG; WORTMANNIN; ANDROSTANE DERIVATIVE; NVP AEW541; NVP-AEW541; PEPTIDE LIBRARY; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SOMATOMEDIN C;

ARTICLE; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOGENESIS; PHAGE DISPLAY; PHASE TRANSITION; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; CELL CYCLE; DNA REPLICATION; DRUG ANTAGONISM; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROSTADIENES; CELL CYCLE; CELL LINE, TUMOR; DNA REPLICATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; PEPTIDE LIBRARY; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 33746087330     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.03.025     Document Type: Article

References (45)

1. Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., and Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 23 (1993) 11217-11221
2. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 9113 (1998) 1393-1396
3. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 5350 (1998) 563-566
4. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91 7 (1999) 620-625
5. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90 12 (1998) 911-915
6. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 2 (1999) 151-156
7. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 9418 (2004) 1346-1353
8. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., and Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 3 (2000) 215-244
9. Quinn K.A., Treston A.M., Unsworth E.J., Miller M.J., Vos M., Grimley C., et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271 19 (1996) 11477-11483
10. Steller M.A., Delgado C.H., Bartels C.J., Woodworth C.D., and Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56 8 (1996) 1761-1765
11. Resnik J.L., Reichart D.B., Huey K., Webster N.J., and Seely B.L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58 6 (1998) 1159-1164
12. Xie Y., Skytting B., Nilsson G., Brodin B., and Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59 15 (1999) 3588-3591
13. Hakam A., Yeatman T.J., Lu L., Mora L., Marcet G., Nicosia S.V., et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30 10 (1999) 1128-1133
14. Krueckl S.L., Sikes R.A., Edlund N.M., Bell R.H., Hurtado-Coll A., Fazli L., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64 23 (2004) 8620-8629
15. Weber M.M., Fottner C., Liu S.B., Jung M.C., Engelhardt D., and Baretton G.B. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95 10 (2002) 2086-2095
16. Schnarr B., Strunz K., Ohsam J., Benner A., Wacker J., and Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89 6 (2000) 506-513
17. Happerfield L.C., Miles D.W., Barnes D.M., Thomsen L.L., Smith P., and Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183 4 (1997) 412-417
18. Bartucci M., Morelli C., Mauro L., Ando S., and Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61 18 (2001) 6747-6754
19. Papa V., Gliozzo B., Clark G.M., McGuire W.L., Moore D., Fujita-Yamaguchi Y., et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53 16 (1993) 3736-3740
20. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., and Plymate S.R. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81 10 (1996) 3774-3782
21. Chott A., Sun Z., Morganstern D., Pan J., Li T., Susani M., et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155 4 (1999) 1271-1279
22. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92 18 (2000) 1472-1489
23. Rosenzweig S.A. What's new in the IGF-binding proteins?. Growth Horm IGF Res 14 5 (2004) 329-336
24. Deshayes K., Schaffer M.L., Skelton N.J., Nakamura G.R., Kadkhodayan S., and Sidhu S.S. Rapid identification of small binding motifs with high-throughput phage display: discovery of peptidic antagonists of IGF-1 function. Chem Biol 9 4 (2002) 495-505
25. Schaffer M.L., Deshayes K., Nakamura G., Sidhu S., and Skelton N.J. Complex with a phage display-derived peptide provides insight into the function of insulin-like growth factor I. Biochemistry 42 31 (2003) 9324-9334
26. Weiss G.A., Watanabe C.K., Zhong A., Goddard A., and Sidhu S.S. Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci USA 97 16 (2000) 8950-8954
27. Kibbey M.M., Jameson M.J., Eaton E.M., and Rosenzweig S.A. Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to IGF-1 binding. Mol Pharmacol (2005)
28. Firth S.M., Ganeshprasad U., and Baxter R.C. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J Biol Chem 273 5 (1998) 2631-2638
29. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., et al. In vivo antitumor activity of NVP-AEW541--A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 3 (2004) 231-239
30. Carrick F.E., Hinds M.G., McNeil K.A., Wallace J.C., Forbes B.E., and Norton R.S. Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance. J Mol Endocrinol 34 3 (2005) 685-698
31. Horney M.J., Evangelista C.A., and Rosenzweig S.A. Synthesis and characterization of insulin-like growth factor (IGF)-1 photoprobes selective for the IGF-binding proteins (IGFBPS). photoaffinity labeling of the IGF-binding domain on IGFBP-2. J Biol Chem 276 4 (2001) 2880-2889
32. Mark S., Kubler B., Honing S., Oesterreicher S., John H., Braulke T., et al. Diversity of human insulin-like growth factor (IGF) binding protein-2 fragments in plasma: primary structure, IGF-binding properties, and disulfide bonding pattern. Biochemistry 44 9 (2005) 3644-3652
33. Forbes B.E., Turner D., Hodge S.J., McNeil K.A., Forsberg G., and Wallace J.C. Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain. J Biol Chem 273 8 (1998) 4647-4652
34. Ho P.J., and Baxter R.C. Characterization of truncated insulin-like growth factor-binding protein-2 in human milk. Endocrinology 138 9 (1997) 3811-3818
35. Yan X., Forbes B.E., McNeil K.A., Baxter R.C., and Firth S.M. Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J Biol Chem 279 51 (2004) 53232-53240
36. Leahy M., Lyons A., Krause D., and O'Connor R. Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5 12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251. J Biol Chem 279 18 (2004) 18306-18313
37. Conover C.A., Ronk M., Lombana F., and Powell D.R. Structural and biological characterization of bovine insulin-like growth factor binding protein-3. Endocrinology 127 6 (1990) 2795-2803
38. Busby Jr. W.H., Klapper D.G., and Clemmons D.R. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions. J Biol Chem 263 28 (1988) 14203-14210
39. Andress D.L., and Birnbaum R.S. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 267 31 (1992) 22467-22472
40. Jones J.I., Gockerman A., Busby Jr. W.H., Camacho-Hubner C., and Clemmons D.R. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 121 3 (1993) 679-687
41. Kricker J.A., Towne C.L., Firth S.M., Herington A.C., and Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 144 7 (2003) 2807-2815
42. Akekawatchai C., Holland J.D., Kochetkova M., Wallace J.C., and McColl S.R. Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 280 48 (2005) 39701-39708
43. Mira E., Lacalle R.A., Gonzalez M.A., Gomez-Mouton C., Abad J.L., Bernad A., et al. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep 2 2 (2001) 151-156
44. Roudabush F.L., Pierce K.L., Maudsley S., Khan K.D., and Luttrell L.M. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 275 29 (2000) 22583-22589
45. Nahta R., Yuan L.X., Zhang B., Kobayashi R., and Esteva F.J. Insulin-like growth factor-i receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 23 (2005) 11118-11128